You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTranylcypromine
Accession NumberDB00752  (APRD00645)
TypeSmall Molecule
GroupsApproved
DescriptionA propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Structure
Thumb
Synonyms
Parnate
Tranilcipromina
Transamine
Tranylcypromin
Tranylcypromine
Tranylcyprominum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ParnateTablet, film coated10 mg/1OralCovis Pharmaceuticals Inc2013-01-14Not applicableUs
ParnateTablet, film coated10 mg/1OralConcordia Pharmaceuticals Inc.2013-01-14Not applicableUs
ParnateTablet10 mgOralGlaxosmithkline Inc1992-12-31Not applicableCanada
Tranylcypromine SulfateTablet, film coated10 mg/1OralActavis Pharma, Inc.2016-02-05Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralREMEDYREPACK INC.2014-04-01Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralRising Pharmaceuticals, Inc.2012-01-09Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tranylcypromine SulfateTablet10 mg/1OralGolden State Medical Supply, Inc.2012-02-10Not applicableUs
Tranylcypromine SulfateTablet10 mg/1OralPar Pharmaceutical, Inc.2006-06-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
JatrosomAristo Pharma
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tranylcypromine Sulfate
13492-01-8
Thumb
  • InChI Key: BKPRVQDIOGQWTG-KAVFMPKWSA-N
  • Monoisotopic Mass: 364.145678435
  • Average Mass: 364.46
DBSALT000960
Categories
UNII3E3V44J4Z9
CAS number155-09-9
WeightAverage: 133.1903
Monoisotopic: 133.089149357
Chemical FormulaC9H11N
InChI KeyAELCINSCMGFISI-YGPZHTELSA-N
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8?,9-/m1/s1
IUPAC Name
(1R)-2-phenylcyclopropan-1-amine
SMILES
N[C@@H]1CC1C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of major depressive episode without melancholia.
Structured Indications
PharmacodynamicsTranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.
Mechanism of actionTranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
TargetKindPharmacological actionActionsOrganismUniProt ID
Amine oxidase [flavin-containing] AProteinyes
inhibitor
HumanP21397 details
Amine oxidase [flavin-containing] BProteinyes
inhibitor
HumanP27338 details
Related Articles
AbsorptionInterindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.
Volume of distribution

1.1-5.7 L/kg

Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life1.5-3.2 hours in patients with normal renal and hepatic function
ClearanceNot Available
ToxicityIn overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineTranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTranylcypromine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tranylcypromine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINETranylcypromine may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcarboseTranylcypromine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololTranylcypromine may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Tranylcypromine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tranylcypromine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Tranylcypromine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Tranylcypromine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Tranylcypromine.Approved
AlbiglutideTranylcypromine may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tranylcypromine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfaxalone.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Tranylcypromine.Approved, Illicit
AliskirenTranylcypromine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
AlogliptinTranylcypromine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Tranylcypromine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Tranylcypromine.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Tranylcypromine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Tranylcypromine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Tranylcypromine.Approved
AmineptineTranylcypromine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tranylcypromine.Approved, Withdrawn
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.Approved, Investigational
AmitriptylineTranylcypromine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineTranylcypromine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amoxapine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Tranylcypromine.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amperozide.Experimental
AmphetamineTranylcypromine may increase the hypertensive activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranylcypromine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Tranylcypromine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Tranylcypromine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Tranylcypromine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tranylcypromine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Tranylcypromine.Approved
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Tranylcypromine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Apraclonidine.Approved
AprepitantThe metabolism of Aprepitant can be decreased when combined with Tranylcypromine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Tranylcypromine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tranylcypromine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tranylcypromine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tranylcypromine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Tranylcypromine.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved
ArticaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Tranylcypromine.Approved, Withdrawn
AtenololTranylcypromine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineTranylcypromine may increase the hypertensive activities of Atropine.Approved, Vet Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Tranylcypromine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Azaperone.Vet Approved
AzelastineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Tranylcypromine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranylcypromine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Baclofen.Approved
BambuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Tranylcypromine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tranylcypromine.Approved
BenazeprilTranylcypromine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideTranylcypromine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinTranylcypromine may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Tranylcypromine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzocaine.Approved
BenzphetamineTranylcypromine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Tranylcypromine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Tranylcypromine.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Tranylcypromine.Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Tranylcypromine.Approved
BethanidineTranylcypromine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bezafibrate.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bifeprunox.Investigational
BimatoprostTranylcypromine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Tranylcypromine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Tranylcypromine.Approved, Investigational
BosentanTranylcypromine may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumTranylcypromine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Tranylcypromine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromazepam.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Tranylcypromine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tranylcypromine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brotizolam.Approved, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Tranylcypromine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tranylcypromine.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.Approved, Investigational
BupranololTranylcypromine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tranylcypromine.Approved, Illicit, Investigational, Vet Approved
BupropionTranylcypromine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tranylcypromine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Tranylcypromine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Tranylcypromine.Approved
CanagliflozinTranylcypromine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanTranylcypromine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilTranylcypromine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe metabolism of Captopril can be decreased when combined with Tranylcypromine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tranylcypromine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Tranylcypromine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carisoprodol.Approved
CaroxazoneTranylcypromine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Tranylcypromine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Tranylcypromine.Approved, Investigational
CeliprololTranylcypromine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Tranylcypromine.Approved, Vet Approved
CetirizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Tranylcypromine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Tranylcypromine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ChlorothiazideTranylcypromine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Tranylcypromine.Approved
ChlorphentermineTranylcypromine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ChlorpropamideTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneTranylcypromine may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.Approved
CilazaprilTranylcypromine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tranylcypromine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Tranylcypromine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tranylcypromine.Approved
CirazolineTranylcypromine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Tranylcypromine.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Tranylcypromine.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Tranylcypromine.Approved
ClemastineTranylcypromine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clenbuterol.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Tranylcypromine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with clomethiazole.Investigational
ClomipramineTranylcypromine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clonazepam.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Tranylcypromine.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Tranylcypromine.Approved, Illicit
ClozapineThe metabolism of Clozapine can be decreased when combined with Tranylcypromine.Approved
CocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tranylcypromine.Approved, Investigational
CryptenamineTranylcypromine may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.Approved, Investigational
CyclothiazideTranylcypromine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dantrolene.Approved
DapagliflozinTranylcypromine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tranylcypromine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Tranylcypromine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Tranylcypromine.Approved, Investigational
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Tranylcypromine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Tranylcypromine.Approved
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Tranylcypromine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with deramciclane.Investigational
DeserpidineTranylcypromine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desflurane.Approved
DesipramineTranylcypromine may increase the serotonergic activities of Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Tranylcypromine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine.Approved, Vet Approved
DexmethylphenidateTranylcypromine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineTranylcypromine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanTranylcypromine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diazepam.Approved, Illicit, Vet Approved
DiazoxideTranylcypromine may increase the hypotensive activities of Diazoxide.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Tranylcypromine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tranylcypromine.Approved
DiethylpropionTranylcypromine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Difenoxin.Approved, Illicit
DihydralazineTranylcypromine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Tranylcypromine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Tranylcypromine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Tranylcypromine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Tranylcypromine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tranylcypromine.Approved
DisopyramideTranylcypromine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Tranylcypromine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Tranylcypromine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Tranylcypromine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doramectin.Vet Approved
DorzolamideTranylcypromine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinTranylcypromine may increase the serotonergic activities of Dosulepin.Approved
DoxapramTranylcypromine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Tranylcypromine.Approved
DoxepinTranylcypromine may increase the serotonergic activities of Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Tranylcypromine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Tranylcypromine.Approved, Investigational
DoxylamineTranylcypromine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Tranylcypromine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Drotebanol.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droxidopa.Approved, Investigational
DulaglutideTranylcypromine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineTranylcypromine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Efavirenz.Approved, Investigational
EfonidipineTranylcypromine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Tranylcypromine.Approved
EmpagliflozinTranylcypromine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilTranylcypromine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTranylcypromine may increase the hypotensive activities of Enalaprilat.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Tranylcypromine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Tranylcypromine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tranylcypromine.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Tranylcypromine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe metabolism of Epinastine can be decreased when combined with Tranylcypromine.Approved, Investigational
EpinephrineTranylcypromine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Tranylcypromine.Approved
EpoprostenolTranylcypromine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTranylcypromine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergonovine.Approved
ErgotamineTranylcypromine may increase the hypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Tranylcypromine.Approved, Investigational
EscitalopramTranylcypromine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineTranylcypromine may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Tranylcypromine.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Tranylcypromine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Estazolam.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tranylcypromine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tranylcypromine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Tranylcypromine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.Approved
EtoperidoneTranylcypromine may increase the serotonergic activities of Etoperidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Tranylcypromine.Approved
ExenatideTranylcypromine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ezogabine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Tranylcypromine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Felbamate.Approved
FelodipineTranylcypromine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamTranylcypromine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Tranylcypromine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tranylcypromine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Tranylcypromine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Tranylcypromine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tranylcypromine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flunitrazepam.Approved, Illicit
FluoxetineTranylcypromine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Tranylcypromine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Tranylcypromine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Tranylcypromine.Approved
FluvoxamineTranylcypromine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Tranylcypromine.Approved, Investigational
FosinoprilTranylcypromine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Tranylcypromine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Tranylcypromine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with gabapentin enacarbil.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Tranylcypromine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Tranylcypromine.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gepirone.Investigational
GliclazideTranylcypromine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTranylcypromine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTranylcypromine may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Tranylcypromine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Glutethimide.Approved, Illicit
GlyburideTranylcypromine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
GuanabenzTranylcypromine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelTranylcypromine may increase the hypotensive activities of Guanadrel.Approved
GuanethidineTranylcypromine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Tranylcypromine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Tranylcypromine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Tranylcypromine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Heroin.Approved, Illicit
HexamethoniumTranylcypromine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexobarbital.Approved
HydracarbazineTranylcypromine may increase the hypertensive activities of Hydracarbazine.Approved
HydralazineTranylcypromine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideTranylcypromine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideTranylcypromine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Tranylcypromine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tranylcypromine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Tranylcypromine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Tranylcypromine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Tranylcypromine.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Tranylcypromine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranylcypromine.Investigational
ImipramineTranylcypromine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.Approved
IndalpineTranylcypromine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideTranylcypromine may increase the hypotensive activities of Indapamide.Approved
IndenololTranylcypromine may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Tranylcypromine.Approved, Investigational
IndoraminTranylcypromine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartTranylcypromine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTranylcypromine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTranylcypromine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTranylcypromine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTranylcypromine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTranylcypromine may increase the hypoglycemic activities of Insulin Lispro.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.Approved
IproclozideTranylcypromine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidTranylcypromine may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanTranylcypromine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidTranylcypromine may increase the hypertensive activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoflurane.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Tranylcypromine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tranylcypromine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Tranylcypromine.Approved, Withdrawn
IsradipineTranylcypromine may increase the hypotensive activities of Isradipine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Tranylcypromine.Approved
KetamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketamine.Approved, Vet Approved
KetanserinTranylcypromine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketobemidone.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tranylcypromine.Approved, Nutraceutical
LabetalolThe metabolism of Labetalol can be decreased when combined with Tranylcypromine.Approved
LacidipineTranylcypromine may increase the hypotensive activities of Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lamotrigine.Approved, Investigational
LanreotideTranylcypromine may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Tranylcypromine.Approved, Investigational
LatanoprostTranylcypromine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineTranylcypromine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Tranylcypromine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tranylcypromine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levomethadyl Acetate.Approved
LevomilnacipranTranylcypromine may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinTranylcypromine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Tranylcypromine.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Linezolid.Approved, Investigational
LiraglutideTranylcypromine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilTranylcypromine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Tranylcypromine.Approved
LithiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lofentanil.Illicit
LofexidineTranylcypromine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Tranylcypromine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Tranylcypromine.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Tranylcypromine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lorcaserin.Approved
LosartanTranylcypromine may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tranylcypromine.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Tranylcypromine.Investigational
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Tranylcypromine.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Tranylcypromine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Vet Approved
ManidipineTranylcypromine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Tranylcypromine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tranylcypromine.Approved
MebanazineTranylcypromine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineTranylcypromine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminTranylcypromine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melperone.Approved
MephedroneTranylcypromine may increase the hypertensive activities of Mephedrone.Investigational
MephentermineTranylcypromine may increase the hypertensive activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tranylcypromine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.Approved, Illicit
MequitazineTranylcypromine may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Tranylcypromine.Approved
MetaraminolTranylcypromine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metaxalone.Approved
MetforminTranylcypromine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTranylcypromine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Tranylcypromine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tranylcypromine.Approved
MethotrimeprazineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineTranylcypromine may increase the hypertensive activities of Methoxamine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tranylcypromine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tranylcypromine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyldopa.Approved
Methylene blueTranylcypromine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateTranylcypromine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Tranylcypromine.Approved, Illicit, Withdrawn
MetipranololTranylcypromine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.Approved, Investigational
MetolazoneTranylcypromine may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tranylcypromine.Approved, Investigational
MetyrosineTranylcypromine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Tranylcypromine.Approved
MianserinTranylcypromine may increase the neurotoxic activities of Mianserin.Approved
MibefradilTranylcypromine may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.Approved, Illicit
MidodrineTranylcypromine may increase the hypertensive activities of Midodrine.Approved
MifepristoneTranylcypromine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTranylcypromine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranTranylcypromine may increase the serotonergic activities of Milnacipran.Approved
MinaprineTranylcypromine may increase the hypertensive activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
MinoxidilTranylcypromine may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Tranylcypromine.Approved
MirtazapineTranylcypromine may increase the central neurotoxic activities of Mirtazapine.Approved
MMDATranylcypromine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.Approved
MoexiprilTranylcypromine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.Approved, Investigational
MorphineThe metabolism of Morphine can be decreased when combined with Tranylcypromine.Approved, Investigational
MoxonidineTranylcypromine may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved, Investigational
NadololTranylcypromine may increase the hypotensive activities of Nadolol.Approved
NaftopidilTranylcypromine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nalbuphine.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
NateglinideTranylcypromine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.Approved, Investigational
NefazodoneTranylcypromine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Tranylcypromine.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Tranylcypromine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Tranylcypromine.Approved
NialamideTranylcypromine may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Tranylcypromine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Tranylcypromine.Approved
NicorandilNicorandil may increase the hypotensive activities of Tranylcypromine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Tranylcypromine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Tranylcypromine.Approved
NiguldipineTranylcypromine may increase the hypotensive activities of Niguldipine.Experimental
NilutamideThe metabolism of Nilutamide can be decreased when combined with Tranylcypromine.Approved
NilvadipineTranylcypromine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineTranylcypromine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTranylcypromine may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitrazepam.Approved
NitrendipineTranylcypromine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tranylcypromine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Tranylcypromine.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tranylcypromine.Approved, Investigational
NitroprussideTranylcypromine may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineTranylcypromine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Normethadone.Approved, Illicit
NortriptylineTranylcypromine may increase the serotonergic activities of Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tranylcypromine.Approved
OctamoxinTranylcypromine may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotideTranylcypromine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olanzapine.Approved, Investigational
OlmesartanTranylcypromine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olopatadine.Approved
OmapatrilatTranylcypromine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Tranylcypromine.Approved
OpipramolTranylcypromine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Orciprenaline.Approved
OrphenadrineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Tranylcypromine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxetacaine.Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Tranylcypromine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tranylcypromine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Tranylcypromine.Approved
ParaldehydeTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineTranylcypromine may increase the hypertensive activities of Pargyline.Approved
ParoxetineTranylcypromine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideTranylcypromine may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Tranylcypromine.Approved
PenbutololTranylcypromine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineTranylcypromine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tranylcypromine.Approved, Vet Approved
PentoliniumTranylcypromine may increase the hypotensive activities of Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Tranylcypromine.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Tranylcypromine.Approved
PerindoprilTranylcypromine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Tranylcypromine.Approved
PethidineTranylcypromine may increase the serotonergic activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tranylcypromine.Withdrawn
PhenelzineTranylcypromine may increase the hypertensive activities of Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Tranylcypromine.Approved, Withdrawn
PheniprazineTranylcypromine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenobarbital.Approved
PhenoxybenzamineTranylcypromine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenoxyethanol.Approved
PhenoxypropazineTranylcypromine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineTranylcypromine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineTranylcypromine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineTranylcypromine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenytoin.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Tranylcypromine.Approved, Illicit
PimozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pimozide.Approved
PinacidilTranylcypromine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Tranylcypromine.Approved
PioglitazoneTranylcypromine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Tranylcypromine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Piritramide.Investigational
PirlindoleTranylcypromine may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineTranylcypromine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenTranylcypromine may increase the anticholinergic activities of Pizotifen.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Tranylcypromine.Approved
PolythiazideTranylcypromine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Tranylcypromine.Approved
PramipexoleTranylcypromine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideTranylcypromine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pramocaine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Tranylcypromine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Tranylcypromine.Approved, Vet Approved
PrazosinTranylcypromine may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tranylcypromine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tranylcypromine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Tranylcypromine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tranylcypromine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Tranylcypromine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tranylcypromine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Tranylcypromine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Tranylcypromine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prothipendyl.Investigational
ProtriptylineTranylcypromine may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Tranylcypromine.Investigational
PSD502The risk or severity of adverse effects can be increased when Tranylcypromine is combined with PSD502.Investigational
PseudoephedrineTranylcypromine may increase the hypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quazepam.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Tranylcypromine.Approved
QuinaprilTranylcypromine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineTranylcypromine may increase the hypoglycemic activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramelteon.Approved, Investigational
RamiprilTranylcypromine may increase the hypotensive activities of Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Tranylcypromine.Approved
RasagilineTranylcypromine may increase the hypertensive activities of Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Tranylcypromine.Approved
RemikirenTranylcypromine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Tranylcypromine.Approved, Withdrawn
RepaglinideTranylcypromine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Tranylcypromine.Investigational
RescinnamineTranylcypromine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.Approved
RilmenidineTranylcypromine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatTranylcypromine may increase the hypotensive activities of Riociguat.Approved
RisperidoneTranylcypromine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritanserin.Investigational
RitobegronTranylcypromine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine.Approved
RitonavirThe metabolism of Ritonavir can be decreased when combined with Tranylcypromine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Tranylcypromine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Tranylcypromine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Romifidine.Vet Approved
RopiniroleTranylcypromine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Tranylcypromine.Approved
RosiglitazoneTranylcypromine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Tranylcypromine.Approved
RotigotineTranylcypromine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tranylcypromine.Approved
SafrazineTranylcypromine may increase the hypertensive activities of Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sage 547.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salmeterol.Approved
SaprisartanTranylcypromine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Tranylcypromine.Approved, Investigational
SaxagliptinTranylcypromine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.Approved, Vet Approved
SelegilineTranylcypromine may increase the hypertensive activities of Selegiline.Approved, Investigational, Vet Approved
SelexipagTranylcypromine may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Tranylcypromine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Tranylcypromine.Approved, Withdrawn
SertralineTranylcypromine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Tranylcypromine.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Tranylcypromine.Approved
SitagliptinTranylcypromine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanTranylcypromine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Tranylcypromine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Tranylcypromine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Tranylcypromine.Experimental
SpiraprilTranylcypromine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Tranylcypromine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Tranylcypromine.Approved
SufentanilSufentanil may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
SulfadiazineTranylcypromine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tranylcypromine.Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
SunitinibTranylcypromine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Tranylcypromine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tandospirone.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tranylcypromine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Tranylcypromine.Investigational, Withdrawn
TelmisartanTranylcypromine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.Approved
TemocaprilTranylcypromine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TeniposideThe metabolism of Teniposide can be decreased when combined with Tranylcypromine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Tranylcypromine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Tranylcypromine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tranylcypromine.Withdrawn
TerlipressinTranylcypromine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Tranylcypromine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Tranylcypromine.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Tranylcypromine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tranylcypromine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrodotoxin.Investigational
TetryzolineTranylcypromine may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tranylcypromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiagabine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Tranylcypromine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiapride.Investigational
TiboloneTranylcypromine may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Tranylcypromine.Approved
TicrynafenTranylcypromine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiletamine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Tranylcypromine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Tranylcypromine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Tranylcypromine.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Tranylcypromine.Approved, Investigational
TolazamideTranylcypromine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTranylcypromine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideTranylcypromine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tranylcypromine.Approved, Withdrawn
ToloxatoneTranylcypromine may increase the hypertensive activities of Toloxatone.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tranylcypromine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Topiramate.Approved
TorasemideTranylcypromine may increase the hypotensive activities of Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tranylcypromine.Approved, Investigational
TramadolTramadol may increase the neuroexcitatory activities of Tranylcypromine.Approved, Investigational
TrandolaprilTranylcypromine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTranylcypromine may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TravoprostTranylcypromine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trazodone.Approved, Investigational
TreprostinilTranylcypromine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Tranylcypromine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triazolam.Approved
TrichlormethiazideTranylcypromine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tranylcypromine.Approved, Vet Approved
TrimazosinTranylcypromine may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Tranylcypromine.Approved
TrimethaphanTranylcypromine may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineTranylcypromine may increase the serotonergic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Tranylcypromine.Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Tranylcypromine.Investigational
Uc1010The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Uc1010.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Tranylcypromine.Approved
UnoprostoneTranylcypromine may increase the hypotensive activities of Unoprostone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tranylcypromine.Approved, Investigational
ValsartanTranylcypromine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineTranylcypromine may increase the serotonergic activities of Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Tranylcypromine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Tranylcypromine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Tranylcypromine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Tranylcypromine.Approved, Investigational
VinpocetineTranylcypromine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Tranylcypromine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Tranylcypromine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Tranylcypromine.Approved
XylazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Xylazine.Vet Approved
XylometazolineTranylcypromine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineThe therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tranylcypromine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Tranylcypromine.Approved
ZimelidineTranylcypromine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tranylcypromine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Tranylcypromine.Approved, Investigational
ZolpidemTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zotepine.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Tranylcypromine.Approved, Investigational
Food Interactions
  • Avoid aged foods (chesse, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St. John's Wort.
References
Synthesis ReferenceNot Available
General References
  1. Frieling H, Bleich S: Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. [PubMed:16927039 ]
  2. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
External Links
ATC CodesN06AF04
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelDownload (152 KB)
MSDSDownload (38.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.7935
P-glycoprotein substrateNon-substrate0.8349
P-glycoprotein inhibitor INon-inhibitor0.9566
P-glycoprotein inhibitor IINon-inhibitor0.9899
Renal organic cation transporterNon-inhibitor0.8659
CYP450 2C9 substrateNon-substrate0.8439
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7604
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.8659
CYP450 2D6 inhibitorNon-inhibitor0.7879
CYP450 2C19 inhibitorInhibitor0.8748
CYP450 3A4 inhibitorNon-inhibitor0.9372
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6942
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6686
BiodegradationReady biodegradable0.5525
Rat acute toxicity2.4266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9807
hERG inhibition (predictor II)Non-inhibitor0.9378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Par pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
Tablet, film coatedOral10 mg/1
TabletOral10 mg/1
Prices
Unit descriptionCostUnit
Parnate 10 mg tablet1.64USD tablet
Tranylcypromine Sulfate 10 mg tablet1.3USD tablet
Tranylcypromine sulf 10 mg tablet1.25USD tablet
Parnate 10 mg Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point79-80 °C at 1.50E+00 mm HgNot Available
water solubility4.86E+004 mg/LNot Available
logP1.58HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.49 mg/mLALOGPS
logP1.5ALOGPS
logP1.34ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity41.7 m3·mol-1ChemAxon
Polarizability15.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00lr-4900000000-a7221eab5a5f5d286c2aView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassAralkylamines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Primary amine
  • Primary aliphatic amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983 ]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723 ]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283 ]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688 ]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268 ]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892 ]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835 ]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840 ]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983 ]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723 ]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283 ]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688 ]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268 ]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892 ]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835 ]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840 ]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB: High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos. 2008 Mar;36(3):614-21. Epub 2007 Dec 19. [PubMed:18094038 ]
  2. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11